Navigation Links
Among the Novel Oral Anticoagulants, Bayer/Janssen's Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
Date:8/29/2013

BURLINGTON, Mass., Aug. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto benefits from its first-to-market advantage for VTE treatment/secondary prophylaxis, the removal of the need for bridging with a low-molecular-weight heparin in the VTE treatment/secondary prophylaxis setting and once-daily dosing. Bristol-Myers Squibb/Pfizer's Eliquis will be Xarelto's closest competitor, but its later launch in both the VTE primary prophylaxis and VTE treatment/secondary prophylaxis markets, as well as its twice-daily dosing, will likely limit its sales relative to Xarelto during the 2012 to 2022 forecast period.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Venous Thromboembolism forecasts that the combined markets for drugs used for both VTE primary prophylaxis and VTE treatment/secondary prophylaxis will grow to $7.3 billion in 2022 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The novel oral anticoagulants are forecast to continue to gain market share at the expense of low-molecular-weight heparins (LMWHs) for VTE prevention following orthopedic surgery. Uptake is higher in Europe where a greater number of novel oral anticoagulants are available for this indication. However, despite this increased uptake, the LMWHs remain the overall market leader in the major markets covered in the report; along with vitamin K antagonists (VKAs), LMWHs continue to dominate the VTE/secondary prophylaxis market, where Xarelto is the only novel oral anticoagulant to have gained approval.

The report also finds that while the failure of the novel oral anticoagulants investigated in clinical trials for VTE primary prophylaxis in the medically ill will limit the growth potential of the VTE market, the overall market will benefit from increased physician awareness of the need for VTE primary prophylaxis following non-orthopedic surgery. However, the main growth driver for the VTE market will be the anticipated launches of the novel oral anticoagulants for VTE treatment/secondary prophylaxis, as their use at the expense of VKAs will mark a paradigm shift in standard treatment practices during the forecast period.

"The anticipated launches of Eliquis, Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Lixiana for VTE treatment/secondary prophylaxis, along with the previously-approved Xarelto will drive growth of the VTE market through 2022," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Growth opportunities for these agents will be restricted to the treatment/secondary prophylaxis market, owing to these agents' inability, to date, to gain a primary prophylaxis label outside of the orthopedic surgery setting."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... SAN FRANCISCO, Calif. , Jan. 16, 2017 /PRNewswire/ ... that on January 3, 2017 and January 16, 2017 ... the grant of inducement stock options to purchase an ... new employees. These awards were granted pursuant to the ... inducement material to the new employees entering into employment ...
(Date:1/16/2017)... , Jan. 16, 2017 CBDRx, the world,s ... amounts of phyto-nutrient rich hemp extract to Veteran,s groups ... of their proprietary hemp extract to Veteran,s groups across ... best hemp company in the world and through their ... nutritious, full spectrum phyto-nutrient rich hemp extract available. ...
(Date:1/15/2017)... 16, 2017 Le conseil d,administration de ... de collagène pour la régénération de tissus humains, annonce la ... directeur général avec effet immédiat. ... Bill est un dirigeant expérimenté à ... postes de gestion générale et de direction au sein de ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... ... 2017 , ... Going above and beyond the practical impact ... communities around the world by offering the Gensuite team and their services to ... members to become involved in a cause that is bigger than themselves and ...
(Date:1/15/2017)... ... 15, 2017 , ... "On Tour is a music themed slideshow production package ... Christina Austin - CEO of Pixel Film Studios. , On Tour’s new slide ... and animation of their slideshows. Place each slide on top of another slide or ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to a ... Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular ... health and wellness benefits linked to a Mediterranean diet are only some of ...
Breaking Medicine News(10 mins):